Genomics

Genya Dana, Ph.D. Joins Avellino as Global Head of Health Policy

Avellino Lab USA

Former Head of Healthcare at the World Economic Forum brings deep knowledge and expertise in genomics, biotechnology and policy design that advances science and technological innovation globally

Avellino Lab USA, Inc. (Avellino) today announced Genya Dana, Ph.D., as Global Head of Health Policy for the company. Genya comes to Avellino from the World Economic Forum (the Forum), where she served as its Head of Healthcare. There, she led an international team focused on cultivating multi-stakeholder partnerships across health and healthcare, including initiatives in precision medicine, women and girls’ health, health equity, and pandemic forecasting and response.

“On behalf of the Board of Directors and myself, we would like to welcome Genya to Avellino and are thrilled to add her exceptional talents and global scientific experience to the company,” says Avellino Founder and Chairman Gene Lee. “We could not have asked for a better professional to lead our policy and partnership work to expand our reach in providing precision medicine solutions globally.”

“It is an honor to welcome Genya to Avellino. I am extremely confident in her ability to help lead our next chapter of growth as we continue to develop our powerful data-centric diagnostic and therapeutic solutions in healthcare,” says Avellino CEO Jon Robson. “Genomic data is the next frontier of developing novel approaches to disease, and Genya’s experience and skill in healthcare policy and partnerships will help the company develop a cross-border genetic data approach that can accelerate outcomes among a wide range of scientific and healthcare institutions.”

“I have dedicated my career to enabling innovative science and technology that improves lives, the economy and the environment. It is extremely gratifying to join a company such as Avellino that shares the same passion as I do for harnessing the genomic revolution and making applications accessible worldwide,” says Ms. Dana. “Enabling advances in health and healthcare requires collaboration, creativity, cutting-edge science and agile policies, and I am excited to bring my expertise in these areas to one of the most exciting biotechnology companies in the US.”

In addition to her previous role at the Forum, Genya also served as its Head of Precision Medicine and Head of Healthcare Initiatives. Prior to this, she held a number of high-profile roles at the US Department of State, which included serving as a negotiator in the United Nations on science, technology and innovation agreements, and leading the development of the US position on synthetic biology and emerging biotechnologies. She has also held a number of community leadership appointments, including serving on the Board of Directors for Innovations in Healthcare; the Board for Responsible Conduct at the International Genetically Engineered Machines (iGEM) Foundation; and the Board of Operations for Ending Workplace Tuberculosis.

Genya received a Ph.D. in Biotechnology and Risk Assessment and a Master of Science in Science, Technology, and Environmental Policy from the University of Minnesota and a Bachelor of Science in Molecular Biology from Emory University.

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybersecurity, go to AI-Techpark.com.

Business Wire

Business Wire is a trusted source for news organizations, journalists, investment professionals and regulatory authorities, delivering news directly into editorial systems and leading online news sources via its multi-patented NX Network. Business Wire has 18 newsrooms worldwide to meet the needs of communications professionals and news media.

Related posts

Sectra extends medical diagnostics business to include genomics IT

PR Newswire

OBiO Technology Goes Public on Shanghai Stock Exchange Today

PR Newswire

Eurofins Core Business Delivers Strong Revenue Growth in Q1 2022

Business Wire